Merck Pulls Plug On Acquired Drug after Safety Review
Merck & Co. Inc. (NYSE:MRK) on Tuesday announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and other hematologic malignancies in the BELLWAVE…
Merck & Co. has halted the development of its investigational drug nemtabrutinib (MK-1026), a Bruton’s tyrosine kinase inhibitor. The discontinuation follows a review by an external Data Monitoring Committee (eDMC), which concluded that the potential benefits may not outweigh the risks. The decision was made after evaluating Phase 3 BELLWAVE-011 trial results.
Merck also suspended the broader BELLWAVE clinical development program, which included BELLWAVE-008 and BELLWAVE-010 trials. The company acquired nemtabrutinib through a deal with Terns Pharmaceuticals Inc. for approximately $6.7 billion. At the EHA 2023 conference, Merck shared positive Phase 1/2 results from the BELLWAVE-001 trial, which demonstrated a 32% objective response rate (ORR) and a 24.4-month median duration of response (mDOR) in patients with B-cell malignancies. Merck's stock declined 2.26% to $140.13 following the news.
Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.